Nevertheless, expression of HER2, MET, EGFR, GLUT1, and CAIX was, as expected, significantly associated with loss of ERα and PR expression in female breast cancer (p<0.001, p = 0.027, p<0.001, p<0.001, p<0.001 respectively), whereas FGFR2 and CAXII were associated with ERα and PR expression (p = 0.003 and p = 0.016; Table 4). Here, FGFR2 is linked to breast carcinoma.